TheraCell, Inc. is a regenerative medicine company which is guided by a team of influential spine surgeons, and regenerative medicine scientists, and led by experienced Medical Device executives. TheraCell is developing the next generation of advanced technologies for tissue repair for both the human and veterinary markets. TheraCell has three synergistic technology platforms. The first of these is a proprietary and patented process for making demineralized bone fibers (DBF™). The second platform is a patented process for infusing demineralized cortical bone powder into cancellous bone to enhance the osteoinductivity of demineralized cancellous bone grafts. The third technology platform is a range of proprietary and patented oxygenation technologies. Oxygenation leads to improved tissue regeneration. TheraCell has developed methodologies and gained patent protection for applying the oxygenation technology to demineralized bone matrix products and other biologic materials. TheraCell products address bone repair in spine, orthopedics and sports medicine, dental grafts, wound care, and skin care. Founded in 2008, the firm is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area. www.theracellinc.com. ECS™, TheraCell DBF™, DBF™ and TheraCell™ are trademarks of TheraCell, Inc.